The Finnish biotech company KÄÄPÄ Biotech announces the launch of the new Nordic Mushrooms product line. The product line has a distribution agreement to the North American market with the nutritional supplement supplier, Nutralliance. KÄÄPÄ Biotech is looking for partner opportunities also in other markets.

KÄÄPÄ Biotech has invested in Ultrasonic Assisted Extraction technology to produce premium quality mushroom extracts.

KÄÄPÄ Biotech specializes in mycological solutions for various industries, such as forestry and food supplement industry. KÄÄPÄ Biotech was founded in 2018 in Finland and the company has grown significantly in the past few years. KÄÄPÄ Biotech has launched the new Nordic Mushrooms wholesale mushroom extract product line, which includes Finnish grown organic chaga (Inonotus obliquus), reishi (Ganoderma lucidum), shiitake (Lentinula edodes), cordyceps (Cordyceps militaris), lion’s mane (Hericium erinaceus), maitake (Grifola frondosa) and turkey tail (Trametes versicolor). The product line includes mushroom extract powders and liquid extract ingredients for the health food and animal food supplement industry, for instance.

KÄÄPÄ Biotech has signed a distribution agreement for the product line to North America with the nutritional supplement company, Nutralliance. “There is an increased demand for high-quality medicinal mushroom products in the North American market area,” says Eric Puro, the CEO of KÄÄPÄ Biotech. “The origin of the ingredients used in the food supplement industry is also getting more important all the time. Our products are 100% of Finnish origin, from the FSC or PEFC certified Finnish sawdust substrate, to growing of mushrooms as well as processing and manufacturing of the mushroom extracts. We have full traceability and transparency in our process from spore to shipment. Therefore we can guarantee premium quality mushroom extracts to the market.”

KÄÄPÄ Biotech has invested in Ultrasonic Assisted Extraction technology which utilizes a combination of hot water and alcohol extraction. The method ensures the bio-availability of the desired bioactive compounds in each mushroom. This is important, because mushroom cell walls are made of chitin. Without an extraction process the compounds of interest are locked within the mushroom cell wall and pass through the human digestive system.

“The fungi kingdom and especially members of the Basidiomycota phylum (mushrooms) hold tremendous potential for natural, safe and effective products that support a wide variety of health concerns as well as general well-being,” says Brian Salerno, CEO of Nutralliance. “To adequately fulfill modern North American consumers’ desires for superior quality in efficacy, safety and traceability as well as sustainability, we wanted to ensure our mycological expert source was able to put checkmarks in all those columns. KÄÄPÄ Biotech is that resource.”